Everything you need - from product insights to professional resources - together in one place to help you deliver exceptional care.
Products
UCBCares Pro provides access to UCB’s growing portfolio of innovative therapies. Currently, you can explore information on Fintepla®▼ (fenfluramine), indicated for the treatment of seizures associated with Dravet syndrome and Lennox–Gastaut syndrome, as an add‑on therapy to other anti-epileptic medicines for patients 2 years of age and older, and Rystiggo®▼ (rozanolixizumab), indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients with anti-AChR or anti-MuSK antibodies.
Additional products and therapeutic areas will be added soon as we continue to expand the platform—bringing you a more complete view of UCB’s offering in Immunology and Neurology.
Fintepla
is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older
Rystiggo
is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG)
Fintepla®▼ (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older.1
Rystiggo®▼ (rozanolixizumab) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Rystiggo currently not reimbursed on the NHS in Scotland.
Zilbrysq®▼ (zilucoplan) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
GB-FA-2600052 | September 2026
